<DOC>
	<DOCNO>NCT01826201</DOCNO>
	<brief_summary>The purpose study determine whether MOL4239 effective adult subject mild moderate plaque psoriasis compare two target lesion subject apply MOL4239 ointment one target lesion placebo ointment contralateral target lesion twice day 28.5 consecutive day .</brief_summary>
	<brief_title>Paired Psoriasis Lesion , Comparative , Study Evaluate MOL4239 Psoriasis</brief_title>
	<detailed_description>This phase 2a , Randomized , Multi-center , Blinded , Paired Psoriasis Lesion , Comparative Placebo-Controlled study evaluate safety , preliminary efficacy pharmacokinetics MOL4239 30 adult subject mild moderate plaque psoriasis . Eligible subject diagnosis mild moderate plaque psoriasis affect 9.9 % body surface area ( BSA ) less , two designate similar target lesion Psoriasis Severity Score least 6 high . Each subject apply 10 % MOL4239 ointment one target lesion placebo ointment contralateral target lesion twice day 28.5 consecutive day .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Adults , male female , 18 72 year age ( inclusive . ) Mild moderate plaque psoriasis lesion total 9.9 % BSA baseline Psoriasis Severity Score ( PSS ) 6 . Identification bilaterally symmetrical approximately equivalent target lesion least 2.5 x 2.5 cm ( ~6 cm2 ) trunk , arm legs mid calf Psoriasis Severity Score ( PSS ) 6 great . Willing avoid tan device exposure treat skin sun . Willing use cosmetic , include lotion , cream , moisturizers treat lesion . Use EucerinÂ® allow nontest site area . Willing forgo systemic topical treatment psoriasis course study . Willing avoid bath swim two hour study drug treatment . Negative urine pregnancy test Screening baseline woman childbearing potential ( WOCP ) . Sexually active WOCP participate study must agree use medically acceptable method contraception study . Must recover effect surgery , minor office surgical procedure , minimum 3 month must elapse day surgery day screen . Presence significant abnormality liver renal function . Presence clinically significant lab abnormality screen . Any significant uncontrolled medical disease . Use antitumor necrosis factor ( TNF ) biologic agent 4 month prior randomization use Stelara 6 month prior randomization . Use , within one month prior baseline study , : 1 ) systemic immunosuppressive drug ( e.g. , tacrolimus ) , 2 ) oral med ( e.g . methotrexate , retinoids , etc. ) . Use within one month prior baseline study : 1 ) Systemic corticosteroid , 2 ) Systemic antibiotic , 3 ) systemic antipsoriatic treatment , 4 ) oral psoralen ultraviolet A ( PUVA ) therapy , 5 ) ultraviolet B ( UVB ) therapy . Use within two week prior baseline study : 1 ) topical antipsoriatic drug , 2 ) topical corticosteroid , 3 ) topical retinoids , 4 ) topical immunosuppressive agent . Current diagnosis unstable form psoriasis treatment area , include guttate , erythrodermic , exfoliative pustular psoriasis . Other inflammatory skin disease treatment area may confound evaluation psoriasis vulgaris . Females pregnant , breast feeding , plan pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>psoriasis</keyword>
</DOC>